Short answer
Cooper Companies (The) (COO) filed its Q3 2025 10-Q quarterly report on Aug 28, 2025 for the quarter ended Jul 31, 2025. Quarterly revenue was $1.1B (up 5.7% year over year) with net income of $98M.
Q3 2025 key financials · XBRL
- Revenue
- $1.1B
- +5.7% YoY · +5.8% QoQ
- Net income
- $98M
- −6.1% YoY · +12.1% QoQ
- Operating margin
- 16.6%
- Gross margin
- 65.3%
- EPS (diluted)
- $0.49
- −5.8% YoY · +11.4% QoQ
Source: XBRL data from the Cooper Companies (The) (COO) Q3 2025 10-Q on SEC EDGAR. USD.
Cooper Companies (The) Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factors identified in this 10-Q versus most recent 10-K
- Competitive risk updated: CooperVision focusing on silicone hydrogel lenses and expanding single-use product franchises like clariti and MyDay amid shifting market modalities
- Regulatory risk: FDA and Chinese NMPA approvals maintained for MiSight 1 day lens, first FDA-approved myopia management product for children aged 8-12
- Operational risk: CooperSurgical faces competitive pressure from technological advances, pricing, and customer service responsiveness in fertility and women's health markets
- Intellectual property risk: Ongoing patent and trademark enforcement worldwide critical to protecting proprietary products and maintaining competitive advantage
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cooper Companies (The) quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.